CN113248407A - 一种多功能芳香胺类化合物及其制备方法和应用 - Google Patents
一种多功能芳香胺类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN113248407A CN113248407A CN202110553495.0A CN202110553495A CN113248407A CN 113248407 A CN113248407 A CN 113248407A CN 202110553495 A CN202110553495 A CN 202110553495A CN 113248407 A CN113248407 A CN 113248407A
- Authority
- CN
- China
- Prior art keywords
- compound
- aromatic amine
- acid
- preparation
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 aromatic amine compound Chemical class 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims abstract description 67
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims abstract description 32
- 150000004982 aromatic amines Chemical class 0.000 claims abstract description 17
- 238000012986 modification Methods 0.000 claims abstract description 11
- 230000004048 modification Effects 0.000 claims abstract description 10
- 150000003672 ureas Chemical class 0.000 claims abstract description 7
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 65
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 62
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 52
- 238000006243 chemical reaction Methods 0.000 claims description 52
- 150000001875 compounds Chemical class 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 40
- 238000004440 column chromatography Methods 0.000 claims description 36
- 239000003208 petroleum Substances 0.000 claims description 31
- YDTKTBLDWKPOTC-UHFFFAOYSA-N 2,2,2-trichloroethyl n-diazocarbamate Chemical compound ClC(Cl)(Cl)COC(=O)N=[N+]=[N-] YDTKTBLDWKPOTC-UHFFFAOYSA-N 0.000 claims description 26
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical group ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 24
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 14
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical group OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims description 13
- 239000004202 carbamide Substances 0.000 claims description 11
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 claims description 8
- DMPZJACLHDWUFS-UHFFFAOYSA-N 1,3-benzothiazole-6-carboxylic acid Chemical group OC(=O)C1=CC=C2N=CSC2=C1 DMPZJACLHDWUFS-UHFFFAOYSA-N 0.000 claims description 7
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 claims description 7
- ACMLKANOGIVEPB-UHFFFAOYSA-N 2-oxo-2H-chromene-3-carboxylic acid Chemical group C1=CC=C2OC(=O)C(C(=O)O)=CC2=C1 ACMLKANOGIVEPB-UHFFFAOYSA-N 0.000 claims description 7
- GCFQXKYHWFWGSB-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalene-1-carboxylic acid Chemical group C1CCCC2=C1C=CC=C2C(=O)O GCFQXKYHWFWGSB-UHFFFAOYSA-N 0.000 claims description 7
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 claims description 7
- 229960002373 loxoprofen Drugs 0.000 claims description 7
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical group OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims description 7
- 229960002703 undecylenic acid Drugs 0.000 claims description 7
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Chemical group OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims description 6
- 238000001212 derivatisation Methods 0.000 claims description 5
- 125000001967 indiganyl group Chemical group [H][In]([H])[*] 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract description 16
- 229910052723 transition metal Inorganic materials 0.000 abstract description 14
- 150000003624 transition metals Chemical class 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 238000005576 amination reaction Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000002194 synthesizing effect Effects 0.000 abstract description 5
- 229930014626 natural product Natural products 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 96
- 239000000047 product Substances 0.000 description 50
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 28
- 238000005160 1H NMR spectroscopy Methods 0.000 description 28
- 238000001514 detection method Methods 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000003054 catalyst Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 239000007858 starting material Substances 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 238000006114 decarboxylation reaction Methods 0.000 description 6
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 5
- 235000010233 benzoic acid Nutrition 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- YPQAFWHSMWWPLX-UHFFFAOYSA-N 1975-50-4 Chemical compound CC1=C(C(O)=O)C=CC=C1[N+]([O-])=O YPQAFWHSMWWPLX-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 3
- FESDHLLVLYZNFY-UHFFFAOYSA-N 2-benzylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1CC1=CC=CC=C1 FESDHLLVLYZNFY-UHFFFAOYSA-N 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- CGMMPMYKMDITEA-UHFFFAOYSA-N 2-ethylbenzoic acid Chemical compound CCC1=CC=CC=C1C(O)=O CGMMPMYKMDITEA-UHFFFAOYSA-N 0.000 description 2
- RVCJOGNLYVNRDN-UHFFFAOYSA-N 4-bromo-2-methylbenzoic acid Chemical compound CC1=CC(Br)=CC=C1C(O)=O RVCJOGNLYVNRDN-UHFFFAOYSA-N 0.000 description 2
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 2
- AJBWNNKDUMXZLM-UHFFFAOYSA-N 4-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=C(C(O)=O)C=C1 AJBWNNKDUMXZLM-UHFFFAOYSA-N 0.000 description 2
- NNJMFJSKMRYHSR-UHFFFAOYSA-N 4-phenylbenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=CC=C1 NNJMFJSKMRYHSR-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 2
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical group ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 1
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- 238000006964 Chan-Lam coupling reaction Methods 0.000 description 1
- 238000006969 Curtius rearrangement reaction Methods 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002894 chemical waste Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000005245 nitryl group Chemical group [N+](=O)([O-])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
- C07C211/46—Aniline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C211/44—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring
- C07C211/45—Monoamines
- C07C211/47—Toluidines; Homologues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/30—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
- C07C273/1836—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety from derivatives of carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/42—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明属于芳香胺类化合物合成技术领域,特别涉及一种多功能芳香胺类化合物及其制备方法和应用。本发明提供一种多功能芳香胺类化合物,还提供一种多功能芳香胺类化合物的制备方法,是在没有过渡金属参与,且,在相对较低的温度条件下,由DMAP催化芳香羧酸的胺化反应,可用于合成一系列多功能芳香胺类化合物,该制备方法目前尚未见文献报道;本发明还提供一种芳基胺的衍生化产物及其制备方法,以及一种多功能芳香胺类化合物在活性分子后期修饰中的应用,可以用于光学活性脲类化合物以及一些重要活性分子的构建,具有作为合成活性药物以及天然产物的发展前景。
Description
技术领域
本发明属于芳香胺类化合物合成技术领域,特别涉及一种多功能芳香胺类化合物及其制 备方法和应用。
背景技术
芳基胺类化合物广泛存在于许多天然产物、生物活性分子以及功能材料,因此如何发展 绿色、高效的催化策略来快速精准的构建这类骨架是有机合成领域一项重要的研究目标。
目前报道合成芳香胺类化合物代表性的方法有以下几种:醛酮的还原胺化、Mitsunobu 反应、Buchwald-Hartwig胺化、Ullmann偶联反应和Chan-Lam偶联反应。这些方法存在着一 些缺点,例如使用过渡金属催化剂、过量的还原试剂、官能团兼容性差以及产生大量的化学 废弃物。
其中,过渡金属催化剂往往价格比较昂贵、有毒且容易在产品中残留;且,过渡金属催 化剂通常对氧气和水分敏感,在反应过程中需要非常严格的操作,限制了这类需要使用过渡 金属催化剂的反应在实际合成中的应用。因此,在医药产品合成中往往会避免使用过渡金属 催化剂。
因此,从原材料简单易得的角度出发,在无过渡金属参与的条件下合成芳香胺类化合物 具有十分重要的意义。
芳香羧酸作为一类多功能合成子具有廉价易得、化学性质稳定、容易存储等优点,近年 来引起了合成化学家的广泛关注,并将其逐渐应用于复杂活性分子的构建。和烷基羧酸的脱 羧转化不同,芳基羧酸的脱羧反应是热力学不利的过程。传统的催化脱羧体系需要使用苛刻 的反应条件,往往会导致反应效率低和底物范围窄等问题。此外,这些反应体系也不可避免 的会用到过渡金属催化剂钯、铜、铑或银等。
通过对已知方法的查阅,我们发现利用芳香羧酸作为原料合成芳胺类的方法有两种:第 一种是Mainolfi教授在170摄氏度高温条件下,使用过渡金属钯和铜作为催化剂实现的脱羧 胺化反应;第二种是Gooβen教授利用金属钯、铜或银在140摄氏度实现脱羧胺化反应。这 两种方法均使用过渡金属钯和铜,并且反应的温度较高。
发明内容
本发明为了解决上述问题,提供一种多功能芳香胺类化合物,还提供一种多功能芳香胺 类化合物的制备方法,是在没有过渡金属参与,且,在相对较低的温度条件下,由DMAP催 化芳香羧酸的胺化反应,用于合成一系列多功能芳香胺类化合物,该制备方法目前尚未见文 献报道;本发明还提供一种多功能芳香胺类化合物在活性分子后期修饰中的应用,可以用于 光学活性脲类化合物以及一些重要活性分子的构建,例如洛索洛芬、3,7,12-三氧杂环戊酸和 十一碳烯酸的后期修饰,具有作为合成活性药物以及天然产物的发展前景。
本发明采用以下技术方案来实现:
一种多功能芳香胺类化合物,具有通式(I)结构:
其中,R为任意取代的2-甲基、2-乙基、2-苄基、2-苯乙基、3-N,N-二甲基、2-甲基-3- 甲氧基、2-甲基-3-硝基、4-苯基、4-甲磺酰基、3-Cl、4-Cl、或2-甲基-4-Br;或,其中,R为任意取代的5,6,7,8-四氢-1-萘甲酸、1-萘甲酸、香豆素-3-羧酸、2-噻吩羧酸、1,3-苯并噻唑-6- 羧酸或环己烷羧酸;或,其中,R为任意取代的具有生物活性的对-(二丙基氨磺酸)苯甲酸。
一种多功能芳香胺类化合物的制备方法,其步骤为:
基于如下反应式:
以通式(Ⅳ)所示的物为原料,与2,2,2-三氯乙氧基羰基叠氮化物、DMAP和K2CO3溶于反应溶剂中得到混合物,将混合物在90℃下搅拌至反应完全,柱层析纯化得到多功能芳香 胺类化合物;
其中,R为任意取代的2-甲基、2-乙基、2-苄基、2-苯乙基、3-N,N-二甲基、2-甲基-3- 甲氧基、2-甲基-3-硝基、4-苯基、4-甲磺酰基、3-Cl、4-Cl或2-甲基-4-Br;或,其中,R为任 意取代的5,6,7,8-四氢-1-萘甲酸、1-萘甲酸、香豆素-3-羧酸、2-噻吩羧酸、1,3-苯并噻唑-6-羧 酸或环己烷羧酸;或,其中,R任意取代的具有生物活性的对-(二丙基氨磺酸)苯甲酸。
DMAP为4-二甲氨基吡啶,是一种绿色、无毒、廉价的催化剂,可在90℃条件下实现通 式(Ⅳ)所示的物与2,2,2-三氯乙氧羰基叠氮类化物的脱羧胺化反应,合成结构新颖的芳香胺 类化合物。
本发明中,所述2,2,2-三氯乙氧基羰基叠氮化物的作用是作为原料,为反应提供氮源; 所述DMAP的作用是作为催化剂;所述K2CO3的作用是活化通式(Ⅳ)所示的物,例如,所述K2CO3用于活化苯甲酸;
进一步的阐述,基于如下反应式:
所述DMAP与2a所示的物2,2,2-三氯乙氧基羰基叠氮化物的反应,生成中间体2-A所 示的物和叠氮基阴离子;在碱性条件下,苯甲酸可以很容易地与2-A所示的物反应生成2-B 所示的物,并在下一催化循环中重新生成具有催化活性的DMAP;随后,2-B所示的物被叠 氮基阴离子攻击,从而通过释放CO2给出14所示的物和2-C所示的物,然后,14所示的物进行Curtius重排得到12所示的物,12所示的物与2-C所示的物迅速反应得到最终产物3ma所示的物;其中,2-B所示的物为混合酸酐;14所示的物为酰基叠氮化物,2-C所示的物为 烷氧基阴离子,12所示的物为异氰酸酯物质,3ma所示的物为胺产物。
优选的方案,所述反应溶剂为DCE,所述DCE为1,2-二氯乙烷。
优选的方案,所述柱层析的洗脱液采用石油醚和乙酸乙酯的体积比为20:1混合物。
一种芳基胺的衍生化产物的制备方法,其步骤为:在常温下,将通式(I)所示的物和 LiOH溶解于CH3CN/H2O后搅拌至反应完全,柱层析纯化得到芳基胺的衍生化产物;所述CH3CN/H2O中CH3CN和H2O的体积比为1:1;通式(I)所示的物为上述多功能芳香胺类 化合物。
本发明中,所述LiOH的作用是帮助通式(I)所示的物脱去Troc基团得到伯胺,CH3CN/H2O的作用是作为溶剂。
本发明的芳基胺的衍生化产物的制备方法,与现有技术相比,无需任何活化剂,外部氧 化剂和过渡金属催化剂即可实现芳基胺的衍生化产物的制备。
一种芳基胺的衍生化产物,采用上述芳基胺的衍生化产物的制备方法制备而成;所述芳 基胺的衍生化产物具有通式(Ⅱ)的结构:
其中,R为任意取代的H、甲基、洛索洛芬、3,7,12-三氧杂环戊基或十一碳烯酸。
一种多功能芳香胺类化合物在光学活性脲类化合物修饰中的应用。
一种不对称脲类化合物的制备方法,其步骤为:将通式(I)所示的物、DIPEA和胺溶解 在DMSO中,将混合物在100℃下搅拌至反应完全,柱层析纯化得到不对称脲类化合物。
本发明中,所述DIPEA为N,N-二异丙基乙胺,DMSO为二甲基亚砜。
一种不对称脲类化合物,采用上述不对称脲类化合物的制备方法制备而成;所述不对称 脲类化合物具有通式(Ⅲ)的结构:
其中,R为环己烷、氧杂环丁胺基或4-甲氧基苄基。
本发明的有益效果是:
1、本发明公开了一种多功能芳香胺类化合物及其制备方法,该制备方法采用DMAP作 为有机绿色催化剂,在无过渡金属催化剂条件下,由芳香羧酸类原料和2,2,2-三氯乙氧羰基叠 氮化物进行脱羧胺化反应,来合成多种取代芳基胺类化合物,其制备方案具有绿色、操作简 单、底物范围广和官能团相容性好等优点。
2、本发明公开了一种芳基胺的衍生化产物的制备方法,与现有技术相比,无需任何活化 剂,外部氧化剂和过渡金属催化剂即可实现芳基胺的衍生化产物的制备。
3、本发明公开了多功能芳香胺类化合物在光学活性脲类化合物修饰中的应用,本发明公 开的多功能芳香胺类化合物可用于洛索洛芬、3,7,12-三氧杂环戊酸或十一碳烯酸等光学活性 脲类化合物的后期修饰,具有作为合成活性药物以及天然产物的发展前景。
具体实施方式
下面将结合实施例,对本发明的技术方案进行清楚、完整地描述。显然,所描述的实施 例仅仅是本发明的一部分实施例,而不是全部的实施例。基于本发明的实施例,本领域普通 技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
下述实施例中,TLC检测的步骤为:将样品溶液用管口平整的毛细管点于离薄层板一端 约1cm处的起点线上,吹干后置薄层板于盛有展开剂(石油醚/乙酸乙酯)的展开槽内,浸入 深度为0.5cm。待展开剂前沿离顶端约1cm附近时,将色谱板取出,吹干后在紫外灯下显色 得以检测。
实施例1
一种多功能芳香胺类化合物及其制备方法。
实施例1-1
将0.2mmol,27.2mg原料邻甲基苯甲酸(Ⅳ-1)与0.3mmol,65.1mg的2,2,2-三氯乙氧基羰基叠氮化物(Ⅴ)、10mol%,2.4mg的DMAP以及0.5eq,13.8mg的K2CO3溶于2mL 的1,2-二氯乙烷中得到混合物,将混合物在90℃下于反应瓶中搅拌3小时,直到TLC检测反 应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接得到本实施例的目标产物(I-1),产率为83%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.75(s,1H),7.22(dd,J=18.7,8.8Hz,2H),7.09(t, J=7.5Hz,1H),6.64(s,1H),4.84(s,2H),2.30(s,3H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=151.9,134.8,130.5,128.5,126.8,125.0,121.7,95.3, 74.5,17.6。
高分辨:理论值:[M+H]+:281.9850,实测值:281.9846。
实施例1-2
将0.2mmol的原料邻乙基苯甲酸(Ⅳ-2)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物 (Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将 混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接 得到本实施例的目标产物(I-2),产率为78%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.72(s,1H),7.26–7.19(m,2H),7.14(t,J=7.4Hz, 1H),6.67(s,1H),4.84(s,2H),2.64(q,J=7.6Hz,2H),1.26(t,J=7.6Hz,3H。
13C NMR(100MHz,CDCl3)δ(ppm)δ=152.2,134.6,134.2,128.6,126.8,125.4,122.4,95.4, 74.5,24.1,13.9。
高分辨:理论值:[M+H]+:296.0006,实测值:296.0001。
实施例1-3
将0.2mmol的原料邻苄基苯甲酸(Ⅳ-3)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物 (Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将 混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接 得到本实施例的目标产物(I-3),产率为73%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.71(s,1H),7.31(t,J=7.2Hz,3H),7.23(s,2H), 7.17(d,J=7.3Hz,3H),6.56(s,1H),4.76(s,2H),4.00(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=152.1,138.7,135.0,131.8,130.8,129.0,128.5, 127.7,126.8,125.4,123.0,95.3,74.4,38.3。
高分辨:理论值:[M+H]+:358.0163,实测值:358.0158。
实施例1-4
将0.2mmol的原料邻苯乙基苯甲酸(Ⅳ-4)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化 物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物, 将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直 接得到本实施例的目标产物(I-4),产率为68%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.55(s,1H),7.29(t,J=7.3Hz,2H),7.25–7.20(m, 3H),7.13(dd,J=18.7,7.1Hz,3H),6.10(s,1H),4.76(s,2H),2.90(s,4H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=152.3,140.9,134.5,133.3,129.8,128.7,128.5, 127.1,126.4,125.8,123.5,95.4,74.4,36.8,33.6。
高分辨:理论值:[M+H]+:372.0319,实测值:372.0312。
实施例1-5
将0.2mmol的原料3-(N,N-二甲基)苯甲酸(Ⅳ-5)与0.3mmol的2,2,2-三氯乙氧基羰 基叠氮化物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到 混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1 柱层析直接得到本实施例的目标产物(I-5),产率为65%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.17(t,J=8.1Hz,1H),6.90(s,2H),6.70(d,J=7.4 Hz,1H),6.49(d,J=6.6Hz,1H),4.81(s,2H),2.94(s,6H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=151.4,151.2,137.9,129.6,108.5,107.0,102.9,95.3, 74.3,40.5。
高分辨:理论值:[M+H]+:311.0115,实测值:311.0117。
实施例1-6
将0.2mmol的原料3-氯苯甲酸(Ⅳ-6)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物(Ⅴ)、 10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物 在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接得到本实施例的目标产物(I-6),产率为79%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.54(s,1H),7.24(s,1H),7.14–6.98(m,2H),4.83 (s,2H)。
13C NMR(100MHz,CDCl3)(ppm)δ=151.3,138.2,134.9,130.1,124.2,119.0,116.9,95.1, 74.6。
高分辨:理论值:[M+H]+:301.9304,实测值:301.9295。
实施例1-7
将0.2mmol的原料对氯苯甲酸(Ⅳ-7)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物(Ⅴ)、 10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物 在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接得到本实施例的目标产物(I-7),产率为78%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.37(d,J=8.5Hz,2H),7.29(d,J=8.8Hz,2H),7.02(s,1H),4.82(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=151.4,135.6,129.2(overlap),120.1,95.1,74.5。
实施例1-8
将0.2mmol的原料4-苯基苯甲酸(Ⅳ-8)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物 (Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将 混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接 得到本实施例的目标产物(I-8),产率为72%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.55(d,J=8.1Hz,4H),7.48(d,J=8.2Hz,2H),7.41(t,J=7.6Hz,2H),7.33(d,J=7.3Hz,1H),7.04(s,1H),4.83(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=151.5,140.2,137.0,136.2,128.8,127.7,127.1, 126.8,119.2,95.2,74.5。
高分辨:理论值:[M+Na]+:365.9826,实测值:365.9824。
实施例1-9
将0.2mmol的原料4-甲磺酰基苯甲酸(Ⅳ-9)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮 化物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直 接得到本实施例的目标产物(I-9),产率为78%。
1H NMR(400MHz,DMSO)δ(ppm)δ=10.69(s,1H),7.88(d,J=8.9Hz,2H),7.75(d,J= 8.6Hz,2H),4.98(s,2H),3.16(s,3H)。
13C NMR(100MHz,DMSO)δ(ppm)δ=151.7,143.2,134.7,128.4,118.3,95.6,73.6,43.8。
高分辨:理论值:[M+Na]+:367.9288,实测值:367.9287。
实施例1-10
将0.2mmol的原料2-甲基-4-溴苯甲酸(Ⅳ-10)与0.3mmol的2,2,2-三氯乙氧基羰基叠 氮化物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层 析直接得到本实施例的目标产物(I-10),产率为77%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.64(s,1H),7.34(d,J=6.0Hz,2H),6.63(s,1H), 4.83(s,2H),2.27(s,3H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=151.8,134.0,133.2,130.5,129.9,123.1,117.8,95.1, 74.6,17.5。
高分辨:理论值:[M+H+2]+:361.8955,实测值:361.8939。
实施例1-11
将0.2mmol的原料2-甲基-3-硝基苯甲酸(Ⅳ-11)与0.3mmol的2,2,2-三氯乙氧基羰基 叠氮化物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱 层析直接得到本实施例的目标产物(I-10),产率为77%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.94(s,1H),7.65(d,J=8.2Hz,1H),7.36(t,J=8.2 Hz,1H),6.92(s,1H),4.85(s,2H),2.41(s,3H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=152.1,151.1,151.1,136.7,126.9,124.3,121.0,95.0, 74.8,13.5。
高分辨:理论值:[M+Na]+:348.9520,实测值:348.9520。
实施例1-12
将0.2mmol的原料2-甲基-3-硝基苯甲酸(Ⅳ-12)与0.3mmol的2,2,2-三氯乙氧基羰基 叠氮化物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱 层析直接得到本实施例的目标产物(I-10),产率为66%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.34(s,1H),7.25(s,1H),7.18(t,J=8.2Hz,1H), 6.71(d,J=8.3Hz,1H),4.83(s,2H),3.83(s,3H),2.16(s,3H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=157.6,151.9,135.4,126.4,114.4,107.0,95.1,76.5, 74.3,55.5,9.6。
高分辨:理论值:[M+H]+:333.9775,实测值:333.9771。
实施例1-13
将0.2mmol的原料苯甲酸(Ⅳ-13)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物(Ⅴ)、 10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接得到本 实施例的目标产物(I-13),产率为66%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=.42(d,J=8.0Hz,2H),7.33(t,J=7.8Hz,2H),7.11 (t,J=7.4Hz,1H),6.97(s,1H),4.82(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=151.5,137.0,129.1,124.1,118.8,95.2,74.4。
实施例1-14
将0.2mmol的原料5,6,7,8-四氢-1-萘甲酸(Ⅳ-14)与0.3mmol的2,2,2-三氯乙氧基羰基 叠氮化物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱 层析直接得到本实施例的目标产物(I-10),产率为92%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.59(s,1H),7.14(t,J=7.8Hz,1H),6.93(d,J=7.6 Hz,1H),6.58(s,1H),4.83(s,2H),2.79(t,J=6.2Hz,2H),2.62(t,J=6.4Hz,2H),1.86(d,J=6.0 Hz,2H),1.78(d,J=5.5Hz,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=152.0,138.2,134.5,126.1,125.9(overlap),119.0, 95.4,74.5,29.7,24.4,22.7,22.4。
高分辨:理论值:[M+Na]+:343.9982,实测值:343.9983。
实施例1-15
将0.2mmol的原料1-萘甲酸(Ⅳ-15)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物(Ⅴ)、 10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接得到本 实施例的目标产物(I-10),产率为66%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=8.02–7.76(m,3H),7.70(d,J=8.3Hz,1H),7.51(t, J=3.3Hz,2H),7.46(t,J=7.9Hz,1H),4.87(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=152.5,134.0,131.5,128.7,126.5,126.2,125.8, 125.6,120.4,119.8,95.3,74.7。
高分辨:理论值:[M+H]+:317.9850,实测值:317.9847。
实施例1-16
将0.2mmol的原料香豆素-3-羧酸(Ⅳ-16)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化 物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物, 将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直 接得到本实施例的目标产物(I-10),产率为75%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=8.34(s,1H),7.82(s,1H),7.55–7.45(m,2H),7.36 (d,J=8.4Hz,2H),4.86(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=158.2,151.3,149.8,129.7,127.6,125.2,123.6, 122.0,119.4,116.4,94.7,74.7。
高分辨:理论值:[M+Na]+:357.9411,实测值:357.9412。
实施例1-17
将0.2mmol的原料2-噻吩羧酸(Ⅳ-17)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将 混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接 得到本实施例的目标产物(I-17),产率为67%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.44(s,1H),6.92(d,J=5.5Hz,1H),6.85(t,J=4.6 Hz,1H),6.70(s,1H),4.84(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=151.7,138.7,124.9,118.4,113.8,94.9,74.9。
高分辨:理论值:[M+H]+:273.9258,实测值:273.9248。
实施例1-18
将0.2mmol的原料1,3-苯并噻唑-6-羧酸(Ⅳ-18)与0.3mmol的2,2,2-三氯乙氧基羰基 叠氮化物(Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱 层析直接得到本实施例的目标产物(I-18),产率为80%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=10.46(s,1H),9.27(s,1H),8.35(s,1H),8.03(d,J= 8.8Hz,1H),7.61(d,J=8.8Hz,1H),4.98(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=154.8,152.0,149.1,136.3,134.4,123.1,118.3, 111.0,95.9,73.5。
高分辨:理论值:[M+Na]+:346.9186,实测值:346.9187。
实施例1-19
将0.2mmol的原料Probenecid(Ⅳ-19)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物(Ⅴ)、 10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将混合物 在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接得到本实施例的目标产物(I-19),产率为59%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.78(d,J=8.6Hz,2H),7.58(d,J=8.5Hz,2H),7.27(s,1H),4.84(s,2H),3.10–3.02(m,4H),1.55(h,J=7.3Hz,4H),0.87(t,J=7.3Hz,6H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=151.2,140.8,134.9,128.4,118.4,94.9,74.6,49.9, 21.9,11.2。
高分辨:理论值:[M+Na]+:453.0180,实测值:453.0179。
实施例1-20
将0.2mmol的原料环己烷羧酸(Ⅳ-20)与0.3mmol的2,2,2-三氯乙氧基羰基叠氮化物 (Ⅴ)、10mol%的DMAP以及0.5eq的K2CO3溶于2mL的1,2-二氯乙烷中得到混合物,将 混合物在90℃下搅拌3小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=20:1柱层析直接 得到本实施例的目标产物(I-20),产率为70%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=4.86(s,1H),4.71(s,2H),3.53(dd,J=11.0,7.1Hz, 1H),1.97(d,J=10.1Hz,2H),1.73(d,J=13.4Hz,2H),1.62(d,J=12.8Hz,1H),1.36(q,J= 12.2Hz,2H),1.19(t,J=11.1Hz,3H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=153.6,95.7,74.3,50.2,33.1,25.4,24.7。
高分辨:理论值:[M+Na]+:295.9982,实测值:295.9981。
实施例2
一种芳基胺的衍生化产物的合成方法,步骤为:
在常温下,将0.2mmol通式(Ⅰ)所示的物和5.0eq的LiOH溶解在2.0mL的CH3CN/H2O中混合后,搅拌5小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=10:1柱层析直接得到 本实施例的目标产物(Ⅱ)。
其中,所述CH3CN/H2O中CH3CN和H2O的体积比为1:1。
其中,通式(Ⅰ)所示的化合物中,R为甲基、乙基、苄基、苯乙基、N-二甲基、甲氧基、硝基、苯基、甲磺酰基、Cl或Br;或,R为5,6,7,8-四氢-1-萘甲酸、1-萘甲酸、香豆素-3-羧酸、2-噻吩羧酸、1,3-苯并噻唑-6-羧酸、环己烷羧酸;或,R为具有生物活性的苯甲酸Probenecid。
其中,通式Ⅱ的化合物中,R为H、甲基、洛索洛芬、3,7,12-三氧杂环戊基、十一碳烯酸。
下述实施例中,所述DCM为二氯甲烷,所述EDC-HCl为1-(3-二甲基氨基丙基)-3-乙基碳二亚胺盐酸盐,所述DMAP为4-二甲氨基吡啶。
实施例2-1
在常温下,将0.2mmol的实施例1-1的目标产物(I-1)和5.0eq的LiOH溶解在2.0mL的CH3CN/H2O中混合后,搅拌5小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=10:1柱 层析直接得到本实施例的目标产物(Ⅱ-1),产率为90%。
本实施例中,所述CH3CN/H2O中CH3CN和H2O的体积比为1:1。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.02(t,J=8.2Hz,2H),6.71(d,J=7.4Hz,1H),6.59(d,J=7.6Hz,1H),3.48(s,2H),2.09(d,J=6.6Hz,3H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=144.4,130.1,126.7,122.0,118.2,114.6,17.0。
实施例2-2
在常温下,将0.2mmol实施例1-13的目标产物(I-13)和5.0eq的LiOH溶解在2.0mL的CH3CN/H2O中混合后,搅拌5小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=10:1柱 层析直接得到本实施例的目标产物(Ⅱ-2),产率为88%。
本实施例中,所述CH3CN/H2O中CH3CN和H2O的体积比为1:1。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.09(t,J=7.4Hz,2H),6.70(t,J=7.1Hz,1H),6.54 (d,J=8.2Hz,2H),3.47(s,2H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=146.2,128.9,118.0,114.7。
实施例2-3
本实施例是在实施例2-2的基础上进一步的发明,提供一种多功能芳香胺类化合物在光 学活性脲类化合物洛索洛芬的后期修饰中的应用。
在充满氩气的情况下,在干燥的圆底烧瓶中装入2.0mL DCM,0.52mmol,1.3eq的EDC-HCl和0.56mmol,1.4eq的DMAP,再将圆底烧瓶在冰浴中冷却至零度,并添加0.4mmol,1.0eq的洛索洛芬(Ⅵ-1),搅拌五分钟后,加入0.48mmol,1.2eq的苯胺(Ⅱ-2),然后移开 冰浴,将反应混合物在室温搅拌下24小时,直到TLC检测原料消耗完全为止,再用5mL的 1MHCl淬灭反应,并分离有机物,最后将用DCM(2×5mL)萃取水层,合并有机层,经 Na2SO4干燥并浓缩,得到产物(Ⅱ-3),最终产率为95%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=7.88(s,1H),7.46(d,J=8.1Hz,2H),7.33–7.18(m, 4H),7.12(d,J=7.9Hz,2H),7.04(t,J=7.4Hz,1H),3.71(q,J=7.1Hz,1H),3.11(dd,J=13.8, 4.1Hz,1H),2.50(dd,J=13.9,9.4Hz,1H),2.38–2.24(m,2H),2.08(dt,J=19.6,10.1Hz,2H), 1.99–1.87(m,1H),1.78–1.63(m,1H),1.54(d,J=7.1Hz,4H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=220.3,172.6,138.9,138.7,137.9,129.2,128.7, 127.5,124.0,119.7,50.8,47.2,38.0,35.0,29.0,20.3,18.5。
高分辨:理论值:[M+H]+:322.1802,实测值:322.1800。
实施例2-4
本实施例是在实施例2-2的基础上进一步的发明,提供一种多功能芳香胺类化合物在光 学活性脲类化合物3,7,12-三氧杂戊酸的后期修饰中的应用。
在充满氩气的情况下,在干燥的圆底烧瓶中装入2.0mL的DCM,0.52mmol、1.3eq的EDC-HCl和0.56mmol、1.4eq的DMAP,再将反应烧瓶在冰浴中冷却至零度,并添加 0.4mmol,1.0eq的3,7,12-三氧杂戊酸(Ⅵ-2),搅拌五分钟后,加入0.48mmol,1.2当量的苯 胺(Ⅱ-2),然后移开冰浴,将反应混合物在室温搅拌下24小时,直到TLC检测原料消耗完 全为止,再用5mL的1M HCl淬灭反应,并分离有机物,最后将用DCM(2×5mL)萃取水 层,合并有机层,经Na2SO4干燥并浓缩,得到产物(Ⅵ-4),最终产率为92%。
在常温下,将0.2mmol的产物(Ⅵ-2)和5.0eq的LiOH溶解在2.0mL的CH3CN/H2O 中混合后,搅拌5小时,直到TLC检测反应完全,以V石油醚/V乙酸乙酯=10:1柱层析直接得到 本实施例的目标产物(Ⅱ-2),产率为92%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=8.00(s,1H),7.52(d,J=7.9Hz,2H),7.28(t,J=7.7 Hz,2H),7.07(t,J=7.4Hz,1H),3.08–2.67(m,3H),2.53–2.17(m,8H),2.17–1.88(m,7H), 1.87–1.75(m,1H),1.69–1.45(m,2H),1.32(d,J=53.4Hz,6H),1.05(s,3H),0.84(d,J=6.6 Hz,3H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=212.2,209.3,209.0,171.8,138.1,128.8,123.9, 119.7,56.8,51.7,48.8,46.7,45.3,45.2,44.9,42.7,38.5,36.3,35.9,35.2,35.1,34.0,30.7,27.5, 25.0,21.7,18.6,11.7。
高分辨:理论值:[M+H]+:478.2952,实测值:478.2953。
实施例2-5
本实施例是在实施例2-2的基础上进一步的发明,提供一种多功能芳香胺类化合物在光 学活性脲类化合物十一碳烯酸的后期修饰中的应用。
在充满氩气的情况下,在火焰干燥的圆底烧瓶中装入2.0mL的DCM,0.52mmol,1.3eq 的EDC-HCl和0.56mmol,1.4eq的DMAP,再将反应烧瓶在冰浴中冷却至零度,并添加0.4mmol,1.0eq的十一碳烯酸(Ⅵ-3),搅拌五分钟后,加入0.48mmol,1.2eq的苯胺(Ⅱ-2),然后移开冰浴,将反应混合物在室温搅拌下24小时,直到TLC检测原料消耗完全为止,再 用5mL的1M HCl淬灭反应,并分离有机物,最后将用DCM(2×5mL)萃取水层,合并有 机层,经Na2SO4干燥并浓缩,得到产物(Ⅱ-5),最终产率为97%。
1H NMR(400MHz,CDCl3)δ(ppm)δ=8.02(s,1H),7.53(d,J=8.0Hz,2H),7.27(t,J=7.7 Hz,2H),7.07(t,J=7.4Hz,1H),5.80(ddt,J=16.9,10.2,6.7Hz,1H),4.95(dd,J=23.8,13.6Hz, 2H),2.33(t,J=7.6Hz,2H),2.02(q,J=7.1Hz,2H),1.68(p,J=7.0Hz,2H),1.41–1.18(m, 10H)。
13C NMR(100MHz,CDCl3)δ(ppm)δ=171.9,139.0,138.0,128.8,124.0,120.0,114.1,37.6, 33.7,29.2,29.2,29.2,29.0,28.8,25.6。
高分辨:理论值:[M+H]+:260.2009,实测值:260.2005。
实施例3
一种以通式Ⅲ所示化合物的合成方法,步骤为:
其中,DIPEA为N,N-二异丙基乙胺,DMSO为二甲基亚砜,yield:产率。
将0.2mmol的实施例1-1的目标产物(I-1),4.0eq的DIPEA和0.3mmol,1.5eq的胺溶解在DMSO中,在100℃下搅拌16小时,通过TLC检测反应完全后,以V石油醚/V乙酸乙酯=1:1 柱层析直接得到本实施例的目标产物通式Ⅲ目标产物。
实施例3-1
将0.2mmol、56.0mg的实施例1-1的目标产物(I-1),4.0eq的DIPEA和0.3mmol,1.5eq的环己胺溶解在DMSO中,在100℃下搅拌16小时,通过TLC分析监测,反应完全后, 以V石油醚/V乙酸乙酯=1:1柱层析直接得到本实施例的目标产物(Ⅲ-1),产率为90%。
1HNMR(400MHz,DMSO)δ(ppm)δ=7.86(d,J=8.1Hz,1H),7.50(s,1H),7.16–7.01(m, 2H),6.83(t,J=7.4Hz,1H),6.51(d,J=7.7Hz,1H),3.45(d,J=8.3Hz,1H),2.16(s,3H),1.87– 1.77(m,2H),1.66(dd,J=8.9,4.2Hz,2H),1.57–1.50(m,1H),1.23(dt,J=49.9,10.9Hz,5H)。
13C NMR(100MHz,DMSO)δ(ppm)δ=154.5,138.4,130.0,126.0(overlap),121.4,119.8, 47.6,33.0,25.3,24.3,17.9。
高分辨:理论值:[M+H]+:233.1648,实测值:233.1646。
实施例3-2
将0.2mmol、56.0mg的实施例1-1的目标产物(I-1),4.0eq的DIPEA和0.3mmol,1.5当量的氧杂环丁胺溶解在DMSO中,将混合物在100℃下搅拌16小时,通过TLC检测反应 完全后,以V石油醚/V乙酸乙酯=1:1柱层析直接得到本实施例的目标产物(Ⅲ-2),产率为92%。
1H NMR(400MHz,DMSO)δ(ppm)δ=7.78–7.66(m,2H),7.27(d,J=6.2Hz,1H),7.14–7.05(m,2H),6.88(t,J=7.4Hz,1H),4.75(p,J=6.9,6.4Hz,3H),4.44–4.38(m,2H),2.18(s, 3H)。
13C NMR(100MHz,DMSO)δ(ppm)δ=154.5,137.8,130.1,127.1,126.1,122.2,120.7,77.9, 44.5,17.8。
高分辨:理论值:[M+H]+:207.1128,实测值:207.1127。
实施例3-3
将0.2mmol、56.0mg的实施例1-1的目标产物(I-1),4.0eq的DIPEA和0.3mmol,1.5当量的(S)-(-)-4-甲氧基-α-甲基苄基胺溶解在DMSO中,将混合物在100℃下搅拌16小 时,通过TLC检测反应完全后,以V石油醚/V乙酸乙酯=1:1柱层析直接得到本实施例的目标产物 (Ⅲ-3),产率为87%。
1H NMR(400MHz,DMSO)δ(ppm)δ=7.86(d,J=8.1Hz,1H),7.58(s,1H),7.26(d,J=8.6Hz,2H),7.12–7.03(m,2H),6.97(d,J=7.7Hz,1H),6.91(d,J=8.6Hz,2H),6.84(t,J=7.5 Hz,1H),4.76(p,J=7.0Hz,1H),3.73(s,3H),2.16(s,3H),1.37(d,J=6.9Hz,3H)。
13C NMR(100MHz,DMSO)δ(ppm)δ=158.0,154.5,138.2,137.1,130.0,127.0,126.0, 126.0,121.6,119.8,113.7,55.1,48.0,23.1,17.9。
高分辨:理论值:[M+H]+:285.1598,实测值:285.1599。
本发明并不限于上述实例,在本发明的权利要求书所限定的范围内,本领域技术人员不 经创造性劳动即可做出的各种变形或修改均受本专利的保护。
Claims (10)
2.一种如权利要求1所述的多功能芳香胺类化合物的制备方法,其特征在于,其步骤为:
基于如下反应式:
以通式(Ⅳ)所示的物为原料,与2,2,2-三氯乙氧基羰基叠氮化物、DMAP和K2CO3溶于反应溶剂中得到混合物,将混合物在90℃下搅拌至反应完全,柱层析纯化得到多功能芳香胺类化合物;
其中,R为2-甲基、2-乙基、2-苄基、2-苯乙基、3-N,N-二甲基、2-甲基-3-甲氧基、2-甲基-3-硝基、4-苯基、4-甲磺酰基、3-Cl、4-Cl或2-甲基-4-Br;
或,其中,R为5,6,7,8-四氢-1-萘甲酸、1-萘甲酸、香豆素-3-羧酸、2-噻吩羧酸、1,3-苯并噻唑-6-羧酸或环己烷羧酸;
或,其中,R具有生物活性的对-(二丙基氨磺酸)苯甲酸。
3.根据权利要求2所述的多功能芳香胺类化合物的制备方法,其特征在于:所述反应溶剂为1,2-二氯乙烷。
4.根据权利要求2所述的多功能芳香胺类化合物的制备方法,其特征在于:所述柱层析的洗脱液采用石油醚和乙酸乙酯的体积比为20:1混合物。
5.一种芳基胺的衍生化产物的制备方法,其特征在于,其步骤为:
将如权利要求1具有通式(I)所示的物和LiOH溶解于CH3CN/H2O后搅拌至反应完全,柱层析纯化得到芳基胺的衍生化产物;所述CH3CN/H2O中CH3CN和H2O的体积比为1:1。
6.根据权利要求5所述的芳基胺的衍生化产物的制备方法,其特征在于,所述反应在常温下进行。
8.一种如权利要求1所述的多功能芳香胺类化合物在光学活性脲类化合物修饰中的应用。
9.一种不对称脲类化合物的制备方法,其特征在于,其步骤为:
将如权利要求1具有通式(I)所示的物、DIPEA和胺溶解在DMSO中,在100℃下搅拌至反应完全,柱层析纯化得到不对称脲类化合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110553495.0A CN113248407A (zh) | 2021-05-20 | 2021-05-20 | 一种多功能芳香胺类化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110553495.0A CN113248407A (zh) | 2021-05-20 | 2021-05-20 | 一种多功能芳香胺类化合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113248407A true CN113248407A (zh) | 2021-08-13 |
Family
ID=77183166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110553495.0A Pending CN113248407A (zh) | 2021-05-20 | 2021-05-20 | 一种多功能芳香胺类化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113248407A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112028814A (zh) * | 2020-09-30 | 2020-12-04 | 南京大学 | 基于新型催化Curtius重排反应制备胺类化合物的方法 |
-
2021
- 2021-05-20 CN CN202110553495.0A patent/CN113248407A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112028814A (zh) * | 2020-09-30 | 2020-12-04 | 南京大学 | 基于新型催化Curtius重排反应制备胺类化合物的方法 |
Non-Patent Citations (1)
Title |
---|
JING ZHANG ET AL.: "Transition-metal-free decarboxylative ipso amination of aryl carboxylic acids", 《ORG. CHEM. FRONT.》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10787420B2 (en) | Benzimidazole compound and preparation method thereof | |
CN106749282A (zh) | 一种治疗卵巢癌药物Rucaparib中间体的制备方法 | |
Wang et al. | PEG-SO3H as catalyst for the Beckmann rearrangement and dehydration of oximes | |
CN111333543B (zh) | 一种利匹韦林中间体的合成方法 | |
CN113248407A (zh) | 一种多功能芳香胺类化合物及其制备方法和应用 | |
CN114751852B (zh) | 一种西咯多辛关键中间体的制备方法 | |
CN109232334A (zh) | 一种甲硫基甲酯的合成方法 | |
CN111362973B (zh) | 一种1,2-苯并噻嗪衍生物的合成方法 | |
US20120149895A1 (en) | Process for dimethylation of active methylene groups | |
CN102127014A (zh) | 一种氮杂菲酮化合物及其制备方法 | |
CN113511986A (zh) | 一种芳基乙腈类衍生物的制备方法 | |
CN110563721A (zh) | 一种新的盐酸阿扎司琼的制备方法 | |
CN111675633A (zh) | 一种n-酰基羟胺的合成方法 | |
CN110804007B (zh) | 一种多取代吡咯衍生物及其制备方法 | |
CN109096139A (zh) | 一种α-羰基酰胺衍生物的制备方法 | |
CN107188909A (zh) | 一种合成吲哚取代或二茂铁取代氮杂芳烃的方法 | |
Eagles et al. | Synthesis of d-camphor based γ-amino acid (1S, 3R)-3-amino-2, 2, 3-trimethylcyclopentane carboxylic acid | |
CN110950865B (zh) | 一种医药中间体8-氯-1,7-萘啶-3-甲醛合成方法 | |
CN115215870B (zh) | 一种喹啉酮类杂环化合物及其合成方法 | |
CN111410656B (zh) | 一种异喹啉酮类衍生物的制备方法 | |
CN115477627B (zh) | 一种多取代2-呋喃酮类化合物及其合成方法 | |
CN101565382A (zh) | 乙酰胺的合成方法 | |
CN114805208A (zh) | 一种4-三氟甲基-4,5-二氢吡唑衍生物及其制备方法 | |
CN115433097A (zh) | 一种无金属制备4-丁氧基苯甲酸(2-二乙胺基乙基)酯的方法 | |
CN117946104A (zh) | 一种水相中碘介导的吲哚并[2,3-b]喹啉类化合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210813 |
|
RJ01 | Rejection of invention patent application after publication |